HUP0001889A2 - COX-2 inhibitort és 5HT1-receptor antagonista hatású vegyületet tartalmazó kombinált gyógyszerkészítmények migrén kezelésére - Google Patents
COX-2 inhibitort és 5HT1-receptor antagonista hatású vegyületet tartalmazó kombinált gyógyszerkészítmények migrén kezeléséreInfo
- Publication number
- HUP0001889A2 HUP0001889A2 HU0001889A HUP0001889A HUP0001889A2 HU P0001889 A2 HUP0001889 A2 HU P0001889A2 HU 0001889 A HU0001889 A HU 0001889A HU P0001889 A HUP0001889 A HU P0001889A HU P0001889 A2 HUP0001889 A2 HU P0001889A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- sulfamyl
- cox
- inhibitor
- pharmaceutical compositions
- Prior art date
Links
- 102000035038 5-HT1 receptors Human genes 0.000 title abstract 2
- 108091005478 5-HT1 receptors Proteins 0.000 title abstract 2
- 208000019695 Migraine disease Diseases 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 229940111134 coxibs Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002545 isoxazoles Chemical class 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- -1 substituted Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
A találmány migrén kezelésére alkalmas kombináltgyógyszerkészítményekre vonatkozik. A találmány szerintigyógyszerkészítmények - adott esetben szokásosan alkalmazottsegédanyagok mellett - az 5HT1-receptor-agonista vegyülettel együtthatóanyag-kombináció formájában magukban foglalnak (a) egy olyanpirazol-származékot, amelynek (I) általános képletében - R1 jelentéseszulfamilcsoport; - R2 jelentése szulfamilcsoport; - R3 jelentéseszulfamilcsoport; - R4 jelentése - adott esetben helyettesített -arilcsoport, cikloalkilcsoport vagy cikloalkenilcsoport; vagy (b) egyolyan izoxazol-származékot, amelynek (II) általános képletében - R1jelentése - többek között - alkilcsoport, alkoxicsoport, alkil-amino-alkil-csoport, halogénatom, aralkil-amino-csoport vagy alkoxi-karbonit-tio-alkil-csoport; - R2 jelentése halogén-alkil-csoport; - R3jelentése - adott esetben helyettesített - cikloalkilcsoport,cikloalkenilcsoport vagy arilcsoport; és - R4 jelentése rövidszénláncú alkilcsoport, hidroxilcsoport vagy aminocsoport. Ó
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13430999P | 1999-05-14 | 1999-05-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU0001889D0 HU0001889D0 (en) | 2000-07-28 |
| HUP0001889A2 true HUP0001889A2 (hu) | 2001-05-28 |
| HUP0001889A3 HUP0001889A3 (en) | 2003-07-28 |
Family
ID=22462766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001889A HUP0001889A3 (en) | 1999-05-14 | 2000-05-12 | Pharmaceutical compositions containing 5ht1 receptor agonists and a cox-2 inhibitor for treating migraine |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1051994A3 (hu) |
| JP (1) | JP2000336031A (hu) |
| KR (1) | KR20010029717A (hu) |
| AU (1) | AU3253800A (hu) |
| CA (1) | CA2308824A1 (hu) |
| CO (1) | CO5170509A1 (hu) |
| HU (1) | HUP0001889A3 (hu) |
| IL (1) | IL136024A0 (hu) |
| PE (1) | PE20010134A1 (hu) |
| ZA (1) | ZA200002343B (hu) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU759307B2 (en) | 1998-11-02 | 2003-04-10 | Merck Sharp & Dohme Corp. | Method of treating migraines and pharmaceutical compositions |
| GB9929039D0 (en) * | 1999-12-08 | 2000-02-02 | Glaxo Group Ltd | Medicaments |
| NL2000351C2 (nl) | 2005-12-22 | 2007-09-11 | Pfizer Prod Inc | Estrogeen-modulatoren. |
| US10198350B2 (en) | 2011-07-28 | 2019-02-05 | Netlist, Inc. | Memory module having volatile and non-volatile memory subsystems and method of operation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
-
2000
- 2000-05-05 AU AU32538/00A patent/AU3253800A/en not_active Abandoned
- 2000-05-08 IL IL13602400A patent/IL136024A0/xx unknown
- 2000-05-09 EP EP00303890A patent/EP1051994A3/en not_active Withdrawn
- 2000-05-10 PE PE2000000434A patent/PE20010134A1/es not_active Application Discontinuation
- 2000-05-10 CO CO00033396A patent/CO5170509A1/es not_active Application Discontinuation
- 2000-05-12 ZA ZA200002343A patent/ZA200002343B/xx unknown
- 2000-05-12 JP JP2000140270A patent/JP2000336031A/ja not_active Abandoned
- 2000-05-12 CA CA002308824A patent/CA2308824A1/en not_active Abandoned
- 2000-05-12 HU HU0001889A patent/HUP0001889A3/hu unknown
- 2000-05-13 KR KR1020000025597A patent/KR20010029717A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20010134A1 (es) | 2001-02-28 |
| HU0001889D0 (en) | 2000-07-28 |
| EP1051994A2 (en) | 2000-11-15 |
| HUP0001889A3 (en) | 2003-07-28 |
| CO5170509A1 (es) | 2002-06-27 |
| CA2308824A1 (en) | 2000-11-14 |
| EP1051994A3 (en) | 2003-01-08 |
| JP2000336031A (ja) | 2000-12-05 |
| KR20010029717A (ko) | 2001-04-16 |
| AU3253800A (en) | 2000-11-16 |
| ZA200002343B (en) | 2001-11-12 |
| IL136024A0 (en) | 2001-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0317717B8 (pt) | composto, composição farmacêutica, e uso de um composto | |
| HUP0301690A2 (hu) | Szinergikus eljárások és készítmények rák kezelésére | |
| MX2022015260A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer. | |
| HUP0203098A2 (hu) | PDE-inhibitorok és béta2 adrenoceptor szinergetikus kombinációja és ezt tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| BR0015193A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas | |
| DE60329316D1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| HUP0303929A2 (hu) | Szubsztituált azetidinon vegyületeket tartalmazó gyógyszerkészítmények alkalmazása szitoszterinémia kezelésére | |
| HUP0001170A2 (hu) | Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények | |
| NO955256D0 (no) | Fenylheterosykluser som syklooksygenase-2-inhibitorer | |
| CY1112084T1 (el) | Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3 | |
| NO20051404L (no) | Pyridylsubstituerte heterocykluser som er nyttige for behandling eller forebyggelse av HCV infeksjon | |
| HUP0103319A2 (hu) | Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk | |
| BR0209468A (pt) | Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar | |
| BR0311931A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente | |
| BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
| BR0317680A (pt) | Composto, composição farmacêutica, uso de um composto, ou de um sal farmaceuticamente aceitável do mesmo, método de tratamento de um ser humano, e, processo para a preparação de um composto | |
| BR9812088A (pt) | Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit | |
| AP1780A (en) | Use of cox-2 inhibitors for preventing immunodeficiency. | |
| BR9812236A (pt) | Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit | |
| HUP0204511A2 (en) | Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas | |
| GR910100067A (el) | Αναστολείς αρωματάσης. | |
| HUP0001889A2 (hu) | COX-2 inhibitort és 5HT1-receptor antagonista hatású vegyületet tartalmazó kombinált gyógyszerkészítmények migrén kezelésére | |
| HUP0105201A2 (hu) | Férfiklimax kezelése ösztrogén agonistákat/antagonistákat és tesztoszteront tartalmazó gyógyászati készítmények alkalmazásával | |
| DE69333285D1 (de) | 2-heterozyklisch-5-hydroxy-1,3-pyrimidinen verwendbar als entzündungswidrigesmittel | |
| BRPI0414448A (pt) | composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio |